CN101675341B - 癌症的生物标志物 - Google Patents

癌症的生物标志物 Download PDF

Info

Publication number
CN101675341B
CN101675341B CN200780051417.9A CN200780051417A CN101675341B CN 101675341 B CN101675341 B CN 101675341B CN 200780051417 A CN200780051417 A CN 200780051417A CN 101675341 B CN101675341 B CN 101675341B
Authority
CN
China
Prior art keywords
use according
peptide
ser
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780051417.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101675341A (zh
Inventor
哈德夫·潘达
理查德·G·L·莫根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Surrey
Original Assignee
University of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Surrey filed Critical University of Surrey
Publication of CN101675341A publication Critical patent/CN101675341A/zh
Application granted granted Critical
Publication of CN101675341B publication Critical patent/CN101675341B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN200780051417.9A 2006-12-19 2007-12-19 癌症的生物标志物 Expired - Fee Related CN101675341B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GB0625321.5 2006-12-19
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
GB0719792.4 2007-10-10
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (2)

Publication Number Publication Date
CN101675341A CN101675341A (zh) 2010-03-17
CN101675341B true CN101675341B (zh) 2017-08-08

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780051417.9A Expired - Fee Related CN101675341B (zh) 2006-12-19 2007-12-19 癌症的生物标志物

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
US20120177672A1 (en) * 2009-07-13 2012-07-12 The University Of Surrey Therapeutic peptides, polypeptides and nucleic acid sequences
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
JP5990274B2 (ja) * 2011-12-05 2016-09-07 ファイジェニクス インコーポレイテッド 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3303616B1 (en) * 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
US20190247461A1 (en) * 2015-09-23 2019-08-15 Centre National De La Recherche Scientifique Homeoproteins for use in the treatment of neurodegenerative disorders
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
WO2018119715A1 (zh) * 2016-12-28 2018-07-05 中国科学院广州生物医药与健康研究院 一种获得t细胞的方法及应用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000498A1 (en) 1997-06-27 1999-01-07 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
CA2347081A1 (en) * 1998-10-19 2000-04-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1290442B1 (en) 2000-05-30 2013-11-13 Aarhus Universitet An assay method for testing plant material for exposure to herbicides using biomarkers
AU2001277521A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Diagnosis of diseases associated with cell signalling
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
AU2002249834B2 (en) 2000-12-24 2008-05-22 Iser Lubocki A method for detecting biomarkers
DE60232059D1 (de) * 2001-03-01 2009-06-04 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP2284279A1 (en) * 2004-12-02 2011-02-16 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gary J. Miller等.Aberrant HOXC Expression Accompanies the Malignant Phenotype in Human Prostate.<CANCER RESEARCH>.2003,第63卷5879–5888. *
Kosaki,K.等.HOXC4 [Homo sapiens].<NCBI GenBank: AAG42145.1>.2000,全文. *

Also Published As

Publication number Publication date
AU2007335999A1 (en) 2008-06-26
WO2008075056A1 (en) 2008-06-26
JP2010513901A (ja) 2010-04-30
CN101675341A (zh) 2010-03-17
IL199241A (en) 2014-03-31
BRPI0720371B8 (pt) 2021-07-27
US20100093558A1 (en) 2010-04-15
BRPI0720371A2 (pt) 2013-12-31
BRPI0720371B1 (pt) 2019-05-28
PL2115472T3 (pl) 2014-05-30
RU2009127774A (ru) 2011-01-27
CA2671939C (en) 2017-10-03
CA2671939A1 (en) 2008-06-26
MX2009006378A (es) 2009-08-24
CY1115178T1 (el) 2016-12-14
NZ577548A (en) 2012-03-30
EP2115472B1 (en) 2013-11-06
PT2115472E (pt) 2014-02-14
EP2115472A1 (en) 2009-11-11
DK2115472T3 (da) 2014-02-10
GB0719792D0 (en) 2007-11-21
AU2007335999B2 (en) 2013-09-05
JP5683108B2 (ja) 2015-03-11
SI2115472T1 (sl) 2014-05-30
US8460882B2 (en) 2013-06-11
ES2445185T3 (es) 2014-02-28
GB0625321D0 (en) 2007-01-24
RU2460075C2 (ru) 2012-08-27

Similar Documents

Publication Publication Date Title
CN101675341B (zh) 癌症的生物标志物
RU2596394C2 (ru) Маркеры для рака эндометрия
EP1800130B1 (en) Methods and compositions for evaluating breast cancer prognosis
JP4936887B2 (ja) 胃ガンの検出用マーカー
EP1601968B1 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
Hudler et al. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics
US20070218512A1 (en) Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
US20090081685A1 (en) Methods and compositions for the detection of ovarian disease
AU2015360694A1 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CA2628390A1 (en) Molecular profiling of cancer
US20140248637A1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
US7951544B1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
US20150011411A1 (en) Biomarkers of cancer
US8703127B2 (en) Methods and materials for the diagnosis of prostate cancers
US20130203059A1 (en) Method for Diagnosis of Bladder Cancer and Related Kits
HK40087642A (zh) 诊断癌症和确定癌症患者的总体生存和无病生存的方法
CN117890588A (zh) Acsl4蛋白作为肝癌微血管侵犯标志物的用途
KR20240161980A (ko) 갑상선암의 진단을 위한 신규한 바이오 마커
Class et al. Patent application title: Method for Diagnosis of Bladder Cancer and Related Kits Inventors: Antonio Feliciello (Parete, IT) Luigi Insabato (Napoli, IT) Assignees: Topogen, Inc.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170808

CF01 Termination of patent right due to non-payment of annual fee